Patents Examined by Christine J. Saoud
  • Methods for treating pain associated with sickle cell disease
    Patent number: 11446311
    Abstract: A method for treating pain experienced by patients with sickle cell disease.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: September 20, 2022
    Inventor: Shahin Fatholahi
  • Nucleic acids encoding modified relaxin polypeptides
    Patent number: 11439710
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: September 13, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Anti-angiogenic therapy of metastatic colorectal cancer
    Patent number: 11439683
    Abstract: The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: September 13, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Tasha Nicholle Sims, Bo Gao, Israel Lowy
  • Vascular endothelial growth factor antagonists
    Patent number: 11434268
    Abstract: The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Donald P. Bottaro, Fabiola Cecchi
  • Saccharide-based biomarkers and therapeutics
    Patent number: 11421039
    Abstract: The invention provides antibodies that specifically bind to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine expressed by a cancer cell or an inflammatory cell. Also provided are compositions including these antibodies, as well as polynucleotides, vectors, host cells, and methods useful for production thereof. Further provided are methods and kits for treating or preventing cancer in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, optionally in combination with another anti-cancer agent. Still further provided are methods and kits for treating or preventing gastrointestinal disease in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: August 23, 2022
    Assignee: B & H Biotechnologies, LLC
    Inventor: Huiru Wang
  • Method for promoting adipocyte differentiation and obesity-related disease treatment
    Patent number: 11414469
    Abstract: Here we show that epigenetic control of Neuregulin-1 (NRG1) affects adipose differentiation of stem cells in vitro. Building on this finding, we established a model in which NRG1 is a white adipose tissue (WAT) specific regulator analogous to the role of NRG4 in black adipose tissue (BAT). In this light, NRG1 functions in a paracrine or autocrine manner to regulate formation of new adipocytes from stem populations, both in vitro and in vivo. In neurons, NRG1 has been shown already to play a similar role, promoting neuronal cell differentiation from progenitors in the vertebrate cortex and retina and even promoting neuronal differentiation in vitro. Similarly, in the heart, NRG1 promotes differentiation of cardiomyocytes from their stem cell progenitors both in vivo and in vitro and for this reason has been successfully tested in clinical trials for heart failure.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: August 16, 2022
    Assignee: American University
    Inventor: John R. Bracht
  • Recombinant bi-functional fusion protein and use thereof
    Patent number: 11407841
    Abstract: Provided is a bi-functional fusion protein as well as its preparation method and use. The bi-functional fusion protein is composed of a monoclonal anti-human CD20 antibody linked to a first extracellular domain of human SIRP?. It is shown in in vitro tests that the bi-functional fusion protein is capable of binding to human CD20 and CD47 simultaneously, thus killing CD20+ tumor cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and is also capable of blocking CD47-SIRP? interaction such that macrophages are activated to attack tumor cells. The bi-functional fusion protein has evident anti-tumor activities.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 9, 2022
    Assignee: Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd.
    Inventors: Wenzhi Tian, Song Li
  • IGFBP7 for prediction of risk of AKI when measured prior to surgery
    Patent number: 11397187
    Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: July 26, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Andrea Horsch, Birgit Klapperich, Dirk Block, Alfred Engel, Johann Karl, Rosemarie Kientsch-Engel, Ekaterina Manuilova, Christina Rabe, Sandra Rutz, Monika Soukupova, Ursula-Henrike Wienhues-Thelen, Peter Kastner, Edelgard Anna Kaiser
  • Long-acting VEGF inhibitors for intraocular neovascularization
    Patent number: 11382955
    Abstract: Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: July 12, 2022
    Assignee: The Regents of the University of California
    Inventor: Napoleone Ferrara
  • Dual-targeting antibody targeting SCF and galectin-1 and use thereof
    Patent number: 11377489
    Abstract: The present invention relates to a dual-targeting antibody targeting stem cell factor (SCF) and galectin-1 and a composition for preventing or treating angiogenesis-related diseases comprising the same. The present invention provides a dual-targeting antibody derived from a human monoclonal antibody which may effectively inhibit angiogenesis by simultaneously neutralizing SCF and galectin-1 involved in angiogenesis, and a pharmaceutical composition for preventing or treating angiogenesis-related diseases comprising the antibody. The dual-targeting antibody according to the present invention may effectively prevent or treat angiogenesis-related diseases by simultaneously neutralizing two targets involved in angiogenesis wherein the angiogenesis-related diseases cause hemorrhaging by blood vessels changing due to abnormal angiogenesis and thus increasing the permeability thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: July 5, 2022
    Assignee: NOVELTY NOBILITY INC.
    Inventor: Sang Gyu Park
  • Methods of treating inflammation with monomeric CXCL12 peptide
    Patent number: 11369662
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: June 28, 2022
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • Mutant FGF21 polypeptide compositions
    Patent number: 11365228
    Abstract: The present invention relates, in one aspect, to certain mutant FGF21 polypeptide constructs. In certain non-limiting embodiments, the construct binds to ?-Klotho more tightly than wild-type FGF21. In certain non-limiting embodiments, the construct has a mutation in at least one residue of SEQ ID NO:3 selected from the group consisting of V188, R203, and L194. In certain non-limiting embodiments, the construct further comprises a stability enhancing domain.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: June 21, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Joseph Schlessinger, Sangwon Lee
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
    Patent number: 11364281
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: June 21, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Method for improving resistance to breakage and eggshell strength
    Patent number: 11358996
    Abstract: Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 14, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Daniel Butz, Zhouzheng Ren, Alexis Jo Piepenburg, Mark Eric Cook
  • Methods of treating colorectal cancer
    Patent number: 11332529
    Abstract: This disclosure provides methods for treating a tumor derived from a colorectal cancer exhibiting a high degree of microsatellite instability in a subject comprising administering to the subject an anti-PD-1 antibody. In some embodiments, the method further comprises administering an anti-CTLA-4 antibody. In some embodiments, the colorectal cancer is rectal cancer, colon cancer, or any combination thereof.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 17, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventor: Michael Axelson
  • Use of FGF21 in methods of increasing exocrine pancreatic secretion
    Patent number: 11318186
    Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the treatment of EPI or pancreatitis resulting from surgical procedures.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 3, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Mangelsdorf, Steven A. Kliewer, Katie C. Coate, Genaro Hernandez
  • Antibody directed against the endothelin receptor beta sub-type
    Patent number: 11312780
    Abstract: Antibodies directed against the endothelin receptor sub-type B, in particular monoclonal antibodies, a fragment or derivative thereof. The present disclosure also relates to the therapeutic, diagnostic use or as a research tool of such an antibody in the field of cancers and in particular glioblastoma.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: April 26, 2022
    Assignee: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    Inventors: Didier Boquet, Frédéric Ducancel, Amaury Herbet, Narciso Costa, Jean-Philippe Hugnot
  • Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
    Patent number: 11311605
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2
    Patent number: 11307209
    Abstract: The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 19, 2022
    Assignee: CÉZANNE S.A.S.
    Inventors: Gaïané Demirdjian, Delphine Espinasse
  • Fusion protein containing TGF-? receptor and medicinal uses thereof
    Patent number: 11274142
    Abstract: The present invention provides a fusion protein containing TGF-? receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-?RII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-? receptor, and the use thereof in the preparation of anti-cancer drug.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 15, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jinming Gu, Xiao Luo, Weikang Tao